C and bromocriptine for strength and stamina

some info I found on the use or vitamin c and bromo: PHARMACOLOGICAL DOSE VITAMIN C AND INTERRUPTED ORAL BROMOCRIPTINE A combination believed, based on clinical experience, to exhibit a synergistic effect on inducing increased somatotropin secretion The use of ascorbic acid mixture as an immune stimulant was discussed above as "vitamin C" . Bromocriptine was discussed immediately above. So why do we here discuss these two agents in combination? The reason is that some combinations exhibit characteristics not noted with either agent alone. Such a cooperative effect is known in pharmacology as "synergy". A perceived synergy of the ascorbate / bromocriptine was recognized in the late 1980's at the Mississippi Baptist Medical Center in Jackson, Mississippi, where patients placed on high dose vitamin C and bromocriptine experienced improvement in strength and stamina much greater than that noted with either agent alone. This was perceived as a possible major advance. In quality of life analyses of subjectively perceived problems in advanced cancer patients, the three worst problems are: loss of physical strength pain loss of stamina Deficits of strength and stamina, as perceived by the patients, are usually not addressed by the conventional physician, and there is no standard of care intervention for these problems. Patients are, however, pleased if the physician or his staff exhibits sufficient concern to define the extent of these problems, and possess sufficient therapeutic knowledge that these symptoms may be successfully treated. It is essential to remember the delay to effective of 1 to 8 weeks onset described in "bromocriptine" applies here. -------------------------------------------------------------------------------- A Bibliography of Literature Pharmacological Dose Vitamin C and Interrupted Oral Bromocriptine Stimulate Growth Hormone by Altering CNS Regulatory Parameters Proposed Mechanism of Clinical Synergy and Potential Benefits of this Combination in Immune Restoration Known Vitamin C Neuropharmacology - Vit. C actively absorbed from the gut by a molecular pump. (1) - Vit. C blood level more than doubles with oral intake of 1gm 4 times daily. (2) - Vit. C actively concentrated in the cerebrospinal fluid (CSF) by a choroid plexus molecular pump. (3) - Vit. C CSF level proportional to blood level. (4) - Vit. C secreted into CSF actively transported into brain parenchyma. (5) - Vit. C most powerful aqueous phase antioxidant. (6) Predicted Vitamin C Neuropharmacology - Catacholamines (dopamine, norepinephrin) oxidatively unstable. (7) (8) - Vit. C prevents/reverses catacolamine oxidative breakdown. (9) (10) (11) - Central catacholamine activity directly modulates GHRH which in turn stimulates GH. (12) - GHRH stimulates GH and/or prolactin. (13) (14) (15) - Dopamine stimulates growth hormone (GH). (16) (17) - Norepinephrin stimulates GH. (18) - Monoclonal pituitary cells may secrete GH, prolactin, or both,with transitional states and secretory shifts induced by hormonal modulation. (19) (20) - Prolactin immunosuppressive. (21) (22) Bromocriptine Neuropharmacology - Bromocriptine (Bcp) blocks prolactin. (23) - Bcp stimulates GH. (24) (25) - GH stimulation associated with pulsatile reductions in somatostatin tone. (26) (27) - Bcp GH secretagogue activity likely arises because Bcp is a somatostatin blocker. (28) - Constant Bcp in time released preparations ineffective as GH secretagogue (29); oral or other intermittent administration essential. (30) - Bcp restores functional CD16 NK activity in hyperprolactinemic states. (31) Documented GH Mediated NK/Macrophage Stimulatory Effects - NK activity dependent on dialysable thymic factor. (32) - NK subset in peripheral blood T-cell derived. (33) - NK activity declines with aging. (34) - GH is primary trophic hormone of thymus gland and thymic restoration possible with GH replacement. (35) - GH stimulates NK cells. (36) (37) (38) - GH stimulates macrophages. (39) (40) (41) GH Mediated Strength/Energy Benefits - GH increases strength, energy. (42) (43) - GH stimulates protein anabolism. (44) (45) Evidence for Increased Vitamin E Requirement With Pharmacologic Doses of Vitamin C - Vit. E deficiency may be developed with pharmacological doses of Vit. C. (46) - Vit. E stimulates helper T-lymphocytes. (47) -------------------------------------------------------------------------------- (1) Mayersohn, M.: Ascorbic acid absorption in man: Pharmacokinetic implications. European J. Pharmacol., 19:140-142, (1972). (2) Komindr, S., Nichoalds, G. E., and Kitabchi, A. E: Bimodal effects of megadose vitamin C on adrenal steroid production in man: An in vivo study. Ann. N.Y. Acad. of Sci., Vol. 498:487-490, (1987). (3) Spector, R.: Vitamin homeostasis in the central nervous system: New England J. of Med., Vol. 296, No. 24:1393-1398 (1977). (4) Spector, R. and Lorenzo, A. V: Ascorbic acid homeostasis in the central nervous system. Am. J. of Physiol., Vol. 225, No. 4:757-763, (1973). (5) Spector, R.: Penetration of ascorbic acid from cerebrospinal fluid into brain. Exp. Neurol., 72:645-653, (1981). (6) Frei, B., England, L., and Ames B. N.: Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl. Acad. Sci. USA, Vol. 86:6377-6381, (1989). (7) Graham, D. G.: On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med., Vol 103:359-362, (1979). (8) Cohen, G.: Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Advances in Neurology, Vol. 45:119-125, edited by Yahr, M.D., and Bergmann, K. J. Raven Press. N.Y., (1986). (9) Reilly, D. K., Hershey, L., Rivera-Calimlim, L., and Shoulson, I.: On-off effects in Parkinson's disease: A controlled investigation of ascorbic acid therapy. Adv. in Neuro., Vol. 37: Experimental Therapeutics of Movement Disorders, edited by Fahn, S., Calne, D. B., and Shoulson, I. Raven Press, N.Y.; pp 51-60, (1983). (10) Tse, D. C. S., McCreery, R. L., and Adams, R. N.: Potential oxidative pathways on brain catecholamines. J. of Med. Chem. Vol. 19, No 1:37-40, (1976). (11) Sullivan, S. G. and Stern, A.: Effects of superoxide dismutase and catalase on catalysis of 6-hydroxydopamine and 6-aminodopamine autoxidation by iron and ascorbate. Biochem. Pharmac., Vol. 30, No. 16:2279-2285, (1981). (12) Muller, E. E.: Neural control of somatotropic function. Physiological Reviews, Vol. 67, No. 3:962-1053, (1987). (13) Asa, S. L., Kovacs, K., Stefaneanu, L., Horvath, E., Billestrup, N., Gonzalez-Manchon, C., and Vale, W.: Pituitary mammosomatotroph adenomas develop in old mice transgenic for growth hormone-releasing hormone. Soc. Exp. Biol. Med.: 232-235, 1990. (14) De Marinis, L., Mancini, A., D'Amico, C., Sambo, P., Tofani, A., Calabro, F., La Brocca, A., and Barbarino, A.: Periovulatory plasma prolactin response to synthetic growth hormone-releasing hormone in normal women. Metabolism, Vol. 38, No. 3:275-277, (1989). (15) Fragoso, J., Barrio, R., Donnay, S., and Hernandez, M.: Chronic stimulation of basal prolactin (PRL) secretion by growth hormone releasing hormone (GHRH) in children with GH neurosecretory dysfunction. Horm. Metab. Res., Vol. 22, No. 1:53-54, (1990). (16) Chihara, K., Kashio, Y., Kita, T., Okimura, Y., Kaji, H., Abe, H., and Fujita, T.: L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.: J. Clin. Endocrinol. Metab., Vol. 62, No. 3:466-473, (1986). (17) Alba-Roth, J., von Creyz, C., Mehltretter, G., Schopohl, J., Muller, O. A., and von Werder, K.: Interaction of L-dopa and GHRH on GH secretion in normal men. J. Endocrinol. Invest. 12:783-787, (1989). (18) Negro-Vilar, A., Ojeda, S. R., Advis, J. P., and McCann, S. M.: Evidence for noradrenergic involvement in episodic prolactin and growth hormone release in ovariectomized rats. Endocrinology, 105:86-91, (1979). (19) Bockafor, F. R. and Schwarz, L. K.: Cultures of GH3 cells contain both single and dual hormone secretors. Endo., Vol. 122, No. 24:762-765, (1988). (20) Bockfor, F. R., and Schwarz, L. K.: Cultures of GH3 cells contain both single and dual hormone secretors. Endo., Vol. 122, No. 2:762-765, (1988). (21) Iwatani, Y., Amino, N., Tachi, J., Kimura, M., Ura, I., Mori, M., Miyai, K., Nasu, M., and Tanizawa, O.: Changes of lymphocyte subsets in normal pregnant and postpartum women: Postpartum increase of NK/K (Leu 7) cells. Am. J. Reprod. Immunol. Microbiol., 18:52-55, (1988). (22) Nicoletti, I., Gerli, R., Orlandi, S., Migliorati, G., Rambotti, F., and Riccardi, C.: Defective natural killer cell activity in puerperal hyperprolactinemia. J. Reprod. Immunol, 15:113-121, (1989). (23) Samaan, N. A.: Prolactinoma, a prevalent gonadoinhibitory tumor, responds well to treatment. Oncology, Vol. 28, No. 1, (1983). (24) Camanni, F., Massara, F., Belforte, L., and Molinatti, G. M.: Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-ergocryptine. J. Clin. Endocrinol. Metab. 40:363-366, (1975). (25) Vance, M. L., Kaiser, D. L., Frohman, L. A., Rivier, J., Vale, W. W., and Thorner, M. O.: Role of dopamine in the regulation of growth hormone secretion: Dopamine and bromocriptine augment growth hormone (GH)releasing hormone-stimulated GH secretion in normal man. J. Clin. Endocrinol. Met., Vol. 64: 1136-1141, (1987). (26) Plotsky, P. M. and Vale, W.: Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science, Vol. 230: 461-463, (1985). (27) Stachura, M. E., Tyler, J. M., and Farmer, P. K.: Combined effects of human growth hormone (GH)-releasing factor-44 (GRF) and somatostatin (SRIF) on post-SRIF rebound release of GH and prolactin: A model for GRF-SRIF modulation of secretion. Endo., Vol. 123, No. 3:1476-1482, (1988). (28) Wood, D. F., Docherty, K., Ramsden, D. B., and Sheppard, M.C.: A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro. Molecular and Cellular Endocrinol. 52:257-261, (1987). Elsevier Scientific Publishers Ireland, Ltd. (29) del Pozo, E., Schluter, K., Nuesch, E., Rosenthaler, J., and Kerp, L: Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LATM) and its effect on release of prolactin and growth hormone. Eur. J. Clin. Pharmacol. 29: 615-618, (1986). (30) Iovino, M., Monteleone, P., and Steardo, L.: Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J. Clin. Endocrinol. Metab. Vol. 69, No. 4:910-913, (1989). (31) Honorati, M. C., Travaglini, P., de Bernardi, B., Scorza, R., Hu, C., Togni, M. E., Radelli, L. Vanoli, M., and Zanussi, C.: NK activity in patients with pathological hyperprolactinemia: effect of bromocriptine. Intern J. Neuroscience, Vol. 51:303-305, (1990). (32) Hamprecht, K., Votsch, W., and Anderer, F. A.: Activation of human monocyte and natural killer cell-mediated tumour cell killing by two dialysable thymic factors. Scand. J. Immunol. 24:59-71, (1986). (33) Schmidt, R. E., Murray, C., Daley, J. F., Schlossman, S. F., and Ritz, J.: A subset of natural killer cells in peripheral blood displays a mature T-cell phenotype. J. Exp. Med., Vol. 164:351-356, (1986). (34) Albright, J. W. and Albright, J. F.: Age-associated impairment of murine natural killer activity. Proc. Natl. Acad. Sci. USA, Vol. 80:6371-6375, (1983). (35) Goff, B. L., Roth, J. A., Arp, L. H., and Incefy, G. S.: Growth hormone treatment stimulates thymulin production in aged dogs. Clin. Exp. Immunol., 68:580-587, (1987). (36) Saxena, Q. B., Saxena, R. K., and Adler, W. H.: Regulation of natural killer activity in vivo. Int. Archs Allergy Appl. Immun., 67:169-174, (1982). (37) Davila, D. R., Brief, S., Simon J., Hammer, R. E., Brinster, R. L., and Kelley, K. W.: Role of growth hormone in regulating T-dependent immune events in aged, nude, and transgenic rodents. J. Neurosci. Res., 18:108-116, (1987). (38) Kelley, K. W., Davila, D. R., Brief, S., Simon, J., and Arkins, S.: A pituitary-thymus connection during aging. Ann. N. Y. Acad. of Sci., Vol. 521:88-98, (1988). (39) Kelley, K.: Growth hormone, lymphocytes, and macrophages. Biochemical Pharmacology, Vol. 38, No. 5:705-713, (1989). (40) Edwards, C. K., Ghiasuddin, S. M., Schepper, J. M., Yunger, L. M., and Kelley, K. W.: A newly defined property of somatotropin: priming of macrophages for production of superoxide anion. Science, Vol. 239:769-771, (1988). (41) Kelley, K. W., Brief, S., Westly, H. J., Novakofski, J., Bechtel, P. J., Simon, J., and Walker, E. R.: Hormonal regulation of the age-associated decline in immune function. Ann. N.Y. Acad. Sci., Vol. 496:91-97, (1987). (42) Pointing, G. A., Ward, H. C., Halliday, D., and Sim, A. J. W.: Protein and energy metabolism with biosynthetic human growth hormone in patients on full intravenous nutritional support. J. Parent. and Ent. Nutri., Vol. 14, No. 5:437-441, (1990). (43) Ward, H. C., Halliday, D., and Sim, A. J. W.: Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann. Surgery, Vol. 206, No. 1:56-61, (1987). (44) Fong, Y., Rosenbaum, M., Tracey, K. J., Raman, G., Hesse, D. G., Matthews, D. E., Leibel, R. L., Gertner, J. M., Fischman, D. A., and Lowry, S. F.: Recombinant growth hormone enhances muscle myosin heavy-chain mRNA accumulation and amino acid accrual in humans. Proc. Natl. Acad. Sci. USA, 86:3371-3374, (1989). (45) Lehmann, S. L., Teasley, K. M., Konstantinides, N. N., Konstantinides, F., and Cerra, F. B.: Growth hormone enables effective nutrition by peripheral vein in postoperative patients: a pilot study. J. Amer. Coll. Nutr., Vol. 9, No. 6:610-615, (1990). (46) Chen, L. H.: An increase in vitamin E requirement induced by high supplementation of vitamin C in rats. Am. J. Clin. Nutr. 34:1036-1041, (1981). (47) Corwin, L. M., Gordon, R. K., and Shloss, J.: Studies of the mode of action of vitamin E in stimulating T-cell mitogenesis. Scand. J. Immunol., 14:565-571, (1981).